[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ciusss de L'Est de l'Île de Montréal\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":699},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,26,0,25,[9,53,83,112,141,164,191,218,245,279,303,323,358,390,416,448,467,489,515,543,569,594,618,645,671],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100642094","self-hypnosis-training-for-migraine-management-hylami-a-pilot-and-proof-of-concept-study-100642094",false,"NCT07644299","Self-Hypnosis Training for Migraine Management (HYlaMI): A Pilot and Proof-of-Concept Study","Self-Hypnosis Training for Migraine Management (HYlaMI): A Pilot and Proof-of-Concept Study of the Intervention Program (ORBIT Phase IIa-IIb)","HYlaMI","Inclusion Criteria:\n\n* Formal diagnosis of migraine for more than one year (physician-issued; self-reported diagnosis accepted)\n* French-speaking\n* No consumption of alcohol or recreational drugs on the morning before group hypnosis sessions (migraine rescue medication is accepted but must be reported if taken before a session)\n* Reliable internet connection\n* Available to follow the 2.5-month self-hypnosis training program\n\nExclusion Criteria:\n\n* Sensory or cognitive impairments that would interfere with comprehension (e.g., deafness)\n* Severe, unstabilized neurological or psychiatric disorder that impairs communication\n* Previous psychological treatment using hypnosis techniques for pain management\n* Current participation in another psychological intervention (potential confounder for anxiety\u002Fdepression outcomes)","ALL","18 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","Migraine is one of the most common and disabling neurological conditions worldwide, affecting approximately 1 billion people. Available pharmacological treatments have significant limitations (side effects, contraindications, medication overuse), highlighting the need for effective non-pharmacological alternatives.\n\nThe HYlaMI program (Self-Hypnosis Training for Migraine Management) is an 8-session group-based telehealth intervention adapted from HYlaDO, a self-hypnosis program developed for chronic pain management at the Hôpital Maisonneuve-Rosemont Pain Clinic (Montréal, Canada). Building on a refinement study conducted in autumn 2025 (CER: 2026-4061), HYlaMI combines heterohypnosis (guided by a trained clinician) and self-hypnosis (practiced autonomously at home using audio recordings) through weekly one-hour video sessions (Zoom\u002FCIUSSS EMTL platform).\n\nThis study combines ORBIT Phase IIa (proof of concept) and Phase IIb (pilot study) objectives. The primary aims are to evaluate the feasibility of the HYlaMI program (retention and adherence rates) and to assess whether it can generate a clinically significant change in migraine-related disability compared to a waitlist control group. Secondary aims include evaluating effects on anxiety and depressive symptoms, pain self-efficacy, situational pain\u002Fanxiety\u002Frelaxation, migraine frequency, intensity and duration, medication intake, work absenteeism, quality of life, and the economic burden of migraine.\n\nA mixed-methods design will be used. Forty adults with a diagnosis of migraine for more than one year will be randomized to either the HYlaMI intervention group (n=20) or a waitlist control group (n=20). Participants will complete validated questionnaires at multiple time points (pre-intervention, mid-intervention, post-intervention, and 4-week follow-up), a weekly migraine diary, and self-hypnosis practice logs. Two semi-structured focus groups will be conducted with intervention group participants to inform program improvement.\n\nIf successful, this study will provide the evidence base required to proceed to a larger randomized controlled trial (ORBIT Phase III).",[28],"Migraine Disorder",[30,31,32,33,34,35,36,37,38,39],"migraine","self-hypnosis","clinical hypnosis","chronic pain","non-pharmacological intervention","telehealth","pain self-efficacy","pilot study","proof of concept","group intervention","NOT_YET_RECRUITING","2026-06-08",{"date":43,"type":44},"2026-06-12","ACTUAL",{"date":46,"type":22},"2026-06-01",{"date":48,"type":22},"2027-09-30",{"name":50,"class":51},"Ciusss de L'Est de l'Île de Montréal","OTHER",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":52},"100509457","phase-2-technical-feasibility-of-modified-early-post-operative-intraperitoneal-chemotherapy-mepic-100509457","NCT05913674","Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)","Inclusion Criteria:\n\n* Patient's age 18 years or older, both genders.\n* In good general health as evidenced by an ECOG score of 0 or 1.\n* Histological diagnosis of appendicular or colorectal tumors with peritoneal carcinomatosis, either synchronous (\\\u003C 12 months after primary diagnosis) or metachronous (\\>12 months after the primary diagnosis)\n* Complete staging defined as: (1)Computed tomography (CT) scan of the chest, abdomen and pelvis. (2) Positron emission tomography (PET) scan when clinically appropriate. (3) Diagnostic laparoscopy reporting Peritoneal carcinomatosis index (PCI) +\u002F- biopsy\n* Meets criteria for recommendation by combined multidisciplinary team and tumor board for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) followed by mEPIC\n* Surgery must be performed within 4-6 weeks following the end of neoadjuvant therapy or 4-6 weeks following the patient's enrollment if no neoadjuvant therapy needed.\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the study duration\n* Hematology: Absolute neutrophil count (ANC) ≥ 1,500\u002F μL; Platelets \\> 75,000\u002F μL.\n* Adequate Renal function Creatinine \\\u003C1.5 x the upper limit of normal (ULN) or calculated creatinine clearance of ≥ 50ml\u002Fmin.\n* Adequate Hepatic function: Bilirubin less than 1.5mg\u002FdL; (except in patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0mg\u002FdL).\n\nExclusion Criteria:\n\nPre-cytoreductive surgery:\n\n* Other malignancies other than appendicular and colorectal neoplasms with peritoneal involvement\n* Inability to complete cytoreductive surgery (ECOG 2 or above) or any patient deemed unfit for surgery\n* Known allergic reaction or major toxicity to Fluorouracil\n* Contraindications to Fluorouracil, including history of coronary spasm and\u002For known dihydropyrimidine dehydrogenase deficiency\n* Pregnancy\n* Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon.\n* Any condition that would preclude the ability to deliver appropriate intraperitoneal (IP) therapy.\n\nPost-cytoreductive surgery:\n\n* Patient deemed not medically suitable to receive mEPIC protocol according to surgical team\n* Uncorrected coagulopathy and\u002For thrombocytopenia and\u002For neutropenia\n* Active infection\n* Hemodynamic and \u002F or respiratory compromise\n* Evidence of extensive intraperitoneal adhesions at the time of surgery which prohibits intraperitoneal therapy, as determined by the operating surgeon.\n* Any condition that would preclude the ability to deliver appropriate IP therapy.",{"count":7,"type":22},[61],"PHASE2","The goal of this prospective phase II unicentric Canadian clinical trial is to clarify the feasibility of modified early post-operative intraperitoneal chemotherapy (mEPIC) following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in the clinical context of peritoneal carcinomatosis from colorectal and appendicular neoplasms.\n\nThe primary objective of this study is to confirm the feasibility of mEPIC by evaluating its completion rate compared to the one of historical standard early post-operative intraperitoneal chemotherapy (EPIC) cohorts. The secondary objectives of the study are to evaluate the safety of the mEPIC protocol by monitoring adverse events arising during the protocol and to assess logistical implementation barriers for the nursing and Oncology pharmacy teams, respectively.\n\nParticipants will undergo a modified schedule of EPIC (mEPIC) designed to maximize therapeutic benefit by exploiting the known pharmacokinetics and pharmacodynamics properties of fluorouracil (5-FU) while limiting the logistical issues of the standard protocol. mEPIC consists in shortening the original protocol from five to two days of postoperative intraperitoneal chemotherapy. Additionally, instead of solely administering a singular 5-FU bolus per 24 hours-period, mEPIC is based on the De Gramont intravenous regimen and consists of administering one intraperitoneal bolus of 5-FU (400 mg\u002Fm2) followed by a 24 hours-intraperitoneal infusion of 5-FU (1200 mg\u002Fm2) on postoperative days 1 and 2.",[64,65,66],"Peritoneal Carcinomatosis","Appendiceal Neoplasms","Colorectal Cancer Metastatic",[68,69,70,71,72,73],"Intraperitoneal chemotherapy","Early post-operative intraperitoneal chemotherapy","Fluorouracil","Hyperthermic intraperitoneal chemotherapy","Cytoreductive surgery","mEPIC","RECRUITING","2026-05-12",{"date":77,"type":44},"2026-05-14",{"date":79,"type":44},"2026-05-01",{"date":81,"type":22},"2028-09",{"name":50,"class":51},{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":91,"enrollmentInfo":92,"targetDuration":4,"studyType":23,"phases":94,"briefSummary":95,"conditions":96,"keywords":99,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":52},"100590818","home-based-tdcs-for-depression-in-bpd-100590818","NCT06972368","Home-Based tDCS for Depression in BPD","Efficacy Study of Enhanced Home-Based Transcranial Direct Current Stimulation (tDCS) on Depressive Symptoms in Borderline Personality Disorder (BPD): A Pilot Randomized Controlled Trial","TENTADIS","Inclusion Criteria:\n\n1. To be aged between 18 and 65.\n2. To meet the DSM-IV criteria for BPD.\n3. To present a moderate depressive episode, defined as a MADRS score ≥ 20 (V1 and V3).\n4. To be capable to consent to participate in the study.\n5. To speak either French or English.\n6. Participants must have a prescribing doctor or mental health professional responsible\n7. To maintain a stable psychopharmacological and psychotherapeutic intervention.\n8. To have access to internet an a smartphone.\n9. To demonstrate proficiency in independently using a tDCS device.\n10. To be able to pick up and return the remote tDCS device.\n\nExclusion Criteria:\n\n\\- 1. To have a history of Epilepsy. 2. To have a contraindication for tDCS Medical Devices. 3. To have a history of Cerebrovascular Surgery. 4. To present scalp Conditions Affecting tDCS Electrode Placement. 5. To have a history of bipolar disorder. 6. To present social or medical conditions limiting the autonomous use of remote tDCS.\n\n7\\. To be pregnant. 8. To be currently undergoing neuromodulation treatment. 9. To be currently using benzodiazepines.","65 Years",{"count":93,"type":22},60,[25],"The present study aims to assess the feasibility of home-based tDCS in remote and urban areas (primary objective).\n\nThe secondary aim is to obtain a preliminary assessment of the efficacy of 14 home-based tDCS sessions in reducing depressive symptoms in BPD patients with moderate to severe depressive episodes and BPD symptoms.\n\nExploratory objectives include assessing the impact on neuropsychological and psychosocial functioning, anxiety, physical activity, sleep disorders, and addiction.\n\nAdditionally, we aim to investigate the sociodemographic and clinical factors that are linked to the most favorable response to tDCS in addressing both depressive and BPD symptoms.\n\nWe also aim to assess the feasibility of using a smartwatch as an outcome measure in this population.\n\nFinally, we intend to gather preliminary data on the effectiveness of an online psychoeducational program specifically designed for patients with BPD.\n\nResearchers will compare active tDCS to sham tDCS to see if active treatment is more effective in treating depression in this population.\n\nParticipants will:\n\n* Receive 14 sessions of either active or sham tDCS over one week, delivered at home\n* Complete psychological and neurocognitive assessments at baseline, post-treatment, and at 6 weeks\n* Wear actigraphy monitors and complete questionnaires to assess sleep, physical activity, and other mental health outcomes\n\nThis trial will also explore the feasibility of delivering tDCS in both urban and rural settings.",[97,98],"Major Depressive Disorder (MDD)","Borderline Personality Disorders",[100,101,102,103],"Neuromodulation","personality","tDCS","Depression","2026-05-04",{"date":106,"type":44},"2026-05-06",{"date":108,"type":44},"2026-01-01",{"date":110,"type":22},"2027-06-01",{"name":50,"class":51},{"id":113,"slug":114,"hasResults":12,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":23,"phases":122,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":52},"100494107","phase-2-melatonin-for-treatment-of-delirium-in-critically-ill-adult-patients-100494107","NCT05713877","Melatonin for Treatment of Delirium in Critically Ill Adult Patients","DELIRE-ICU: A Randomised Controlled Feasibility Trial of Melatonin vs Placebo in the Treatment of Delirium in the Intensive Care Unit","DELIRE-ICU","Inclusion Criteria:\n\n* Patients aged 18 years or older admitted to the intensive care unit;\n* Anticipated ICU stay \\> 48 hours;\n* ICDSC score greater than or equal to 4 for a maximum of 48 hours prior to randomization.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to melatonin or to ingredients in ORA-BLEND SF®;\n* Use of melatonin within 24 hours prior to randomization;\n* Presence of severe structural brain injury (intracranial hemorrhage or traumatic brain injury), severe major neurocognitive disorder, advanced neurodegenerative disease or hepatic encephalopathy;\n* Diagnosis of schizophrenia, bipolar affective disorder, psychotic depression, uremic encephalopathy or alcohol withdrawal;\n* Presence of active seizures, coma, aphasia or severe intellectual disability;\n* Limited short-term vital prognosis;\n* Diagnosis of delirium prior to ICU admission;\n* Pregnancy or breastfeeding;\n* Absolute contraindication to receive enteral medication;\n* Inability to understand or speak English or French;\n* Total blindness.",{"count":121,"type":22},30,[61],"The purpose of this study is to determine the feasibility of conducting a randomized controlled trial (RCT) with melatonin for treatment of delirium in critically ill adult patients. From a feasibility perspective, the investigators believe that the proposed design will achieve the minimum enrollment rate necessary to conduct a future RCT on a larger scale.",[125],"Delirium",[127,128,129,130,131,132],"Melatonin","Intensive care","Feasibility","Treatment","Critically ill","ICU","2026-03-19",{"date":135,"type":44},"2026-03-23",{"date":137,"type":44},"2023-02-01",{"date":139,"type":22},"2026-12-30",{"name":50,"class":51},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":148,"minAge":19,"maxAge":4,"enrollmentInfo":149,"targetDuration":151,"studyType":152,"phases":4,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":52},"100537580","improvement-of-womens-health-after-allogeneic-stem-cell-transplantation-100537580","NCT06279676","Improvement of Women's Health After Allogeneic Stem Cell Transplantation","SaFeGreff","Inclusion Criteria:\n\n* All women aged 18 and over who will receive a first allogeneic HSCT (bone marrow, peripheral blood stem cells from a related, unrelated (including cord blood) or haploidentical donor) at the CIUSSS-EMTL. Recruitment will begin when the project receives ethical approval. Recruitment period will be of 2 to 3 years.\n\nExclusion Criteria:\n\n1. Those who receive a second HSCT allograft.\n2. Those who receive an autologous transplant.\n3. Inability to give informed consent.\n4. Unable to communicate in French or English.\n5. Any other reason which, according to the investigators, makes it preferable for a patient not to participate.","FEMALE",{"count":150,"type":22},100,"24 Months","OBSERVATIONAL","The aim of this prospective research project is to better understand vulvovaginal cGVHD to improve care of allografted women. The expected outcomes include better knowledge of the incidence and manifestations of vulvovaginal cGVHD, risk factors, response to treatments and impact on sexual health of allotransplanted female patients. The knowledge acquired will allow transplant clinicians to make more precise recommendations for gynecological management of future allografted women.",[155],"GVHD, Chronic","2026-03-16",{"date":158,"type":44},"2026-03-18",{"date":160,"type":44},"2024-08-27",{"date":162,"type":22},"2028-12",{"name":50,"class":51},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":170,"eligibilityCriteria":171,"healthyVolunteers":172,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":175,"conditions":176,"keywords":181,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":4},"100626595","a-survey-for-patients-and-caregivers-aiming-to-understand-and-improve-the-care-of-patients-at-high-risk-of-transfer-from-peritoneal-dialysis-to-hemodialysis-100626595","NCT07437677","A Survey for Patients and Caregivers Aiming to Understand and Improve the Care of Patients at High Risk of Transfer From Peritoneal Dialysis to Hemodialysis:","Understand, Plan and Improve Care and Wellbeing of Patients at High Risk of Transfer From Peritoneal Dialysis to Hemodialysis - Phase 2 (Survey)","ULIFT-PD","Inclusion Criteria:\n\n1. Adult (≥18 years)\n2. One of the following:\n\n   * Patient who experienced a PD-to-HD transition in past 12 months\n   * Patient currently receiving peritoneal dialysis\n   * Caregiver (self-defined, including spouses, family members, or friends) of individuals meeting the above criteria\n3. Able to read English or French\n4. Able to complete the survey in paper or web-based format\n5. Able to provide informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C18 years\n* Unable to provide consent",true,{"count":174,"type":22},200,"Home dialysis is encouraged in Canada and peritoneal dialysis is the most common home dialysis method. However, many patients discontinue peritoneal dialysis, often transferring to hemodialysis. Despite the frequency of this transition, little is known about its impact on patients.\n\nOverall, the UPLIFT-PD program aims to fill this gap by studying the transition from peritoneal dialysis to hemodialysis. The specific goal of this mixed methods sub-study is to conduct a national survey to ask patients and caregivers about priorities and preferences when they anticipate a transfer from peritoneal dialysis to hemodialysis. This survey will be co-created by patient-partners and dialysis experts.\n\nResults from this survey will then be used in other phases of UPLIFT-PD program, detailed in other registrations, which will support people facing a transition from peritoneal dialysis to hemodialysis..",[177,178,179,180],"Peritoneal Dialysis (PD)","Hemodialysis","Kidney Replacement Therapy","Transition",[182],"Transfer to hemodialysis","2026-02-24",{"date":185,"type":44},"2026-02-27",{"date":187,"type":22},"2027-01",{"date":189,"type":22},"2029-12",{"name":50,"class":51},{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":52},"100551302","quality-of-life-in-patients-transitioning-to-home-or-in-center-dialysis-qualify-ckd-to-home-100551302","NCT06458322","Quality of Life in Patients Transitioning to Home or In-Center Dialysis (QUALIFY CKD-to-HOME)","Prospective Changes in Quality of Life and Frailty in Chronic Kidney Disease Patients Transitioning to Home Versus In-Center Dialysis (QUALIFY CKD-to-HOME Study)","Inclusion Criteria:\n\n* Adult patients followed in advanced CKD clinic;\n* eGFR ≤12 mL\u002Fmin\u002F1.73m2 96;\n* Understand English or French.\n\nExclusion Criteria:\n\n* Orientation toward conservative treatment;\n* Planned kidney transplantation \\\u003C 6 months;\n* Unable to provide consent due to severe cognitive or psychiatric disease;\n* Previous treatment with dialysis \\> 3 month;\n* Life expectancy \\\u003C 6 months.",{"count":174,"type":22},"The goal of this study is to evaluate quality of life (QoL) and frailty trajectories from advanced chronic kidney disease (CKD) to after dialysis initiation, specifically comparing patients choosing home dialysis and in-center hemodialysis.\n\nThe main questions it aims to answer are:\n\n1. What is the trajectory of QoL in patients transitioning from advanced CKD to dialysis (up to 12 months after initiation) and how does these changes differ for patients oriented towards home dialysis and in-center hemodialysis?\n2. Is the development of frailty after dialysis initiation less likely in patient pursuing home dialysis?\n3. What is the variation in other PROMs and health outcomes (fatigue, anxiety \\& depression, general assessment, cognitive function) form advanced CKD to the first 12 months after dialysis initiation?\n4. What are the predictors of severe decline in QoL, frailty and other important health outcomes (fatigue, cognition, anxiety \\& depression) during CKD G5 follow-up and after 12 months post dialysis initiation?\n\nParticipants will be ask to:\n\n* Answer some questions and complete questionnaires each 3 months;\n* Do a a grip test and a walking test each 6 months to evaluate their frailty;",[201],"Chronic Kidney Diseases",[201,203,204,205,206,207,208,209,178],"Quality of Life","Frailty","Dialysis","Home dialysis","In-center dialysis","Peritoneal dialysis","Home hemodialysis","2026-02-20",{"date":212,"type":44},"2026-02-23",{"date":214,"type":44},"2022-07-01",{"date":216,"type":22},"2027-12-31",{"name":50,"class":51},{"id":219,"slug":220,"hasResults":12,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":224,"eligibilityCriteria":225,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":226,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":228,"conditions":229,"keywords":231,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":244,"locationsCount":52},"100542691","prediction-of-propofol-effect-site-concentration-associated-with-deep-anesthesia-100542691","NCT06346158","Prediction of Propofol Effect-Site Concentration Associated With Deep Anesthesia","Prediction of Propofol Effect-Site Concentration Associated With Deep Anesthesia During Induction of General Anesthesia Based on Electroencephalographic Features: a Prospective Observational Study","PRESCOD-AI","Inclusion Criteria:\n\n* Scheduled for any kind of surgery under general anesthesia.\n* Adults\n\nExclusion Criteria:\n\n* Inability to communicate in French or English,\n* Known allergy or intolerance or other medical condition that precludes the use of prescribed general anesthesia protocol for this study,\n* Patients requiring rapid sequence induction,\n* Anticipated or known difficult intubation patient,\n* Anticipated or known difficult ventilation patient,\n* Body mass index ≥ 35 kg.m-2.",{"count":227,"type":22},110,"The goal of this observational study is to explore the variability of the concentration at the effect site (Ce) of propofol to reach deep anesthesia (DA) during induction of general anesthesia in adults.\n\nThe investigators hypothesized that there is a great variability in this Ce that could be precisely explained by\n\n* Electroencephalographic (EEG) features available prior to induction of anesthesia\n* Cognitive performance\n* Patients characteristics Participants will undergo preoperative cognitive testing and awake EEG. Then, induction of general anesthesia will be performed using continuous infusion of propofol. The Ce at which Deep anesthesia is observed will be recorded.",[230],"Anesthesia",[232,233,234,235,236,237],"general anesthesia","propofol","interindividual variability","prediction","cognitive performance","electroencephalogram","2026-01-15",{"date":240,"type":44},"2026-01-16",{"date":242,"type":44},"2025-04-07",{"date":187,"type":22},{"name":50,"class":51},{"id":246,"slug":247,"hasResults":12,"nctId":248,"briefTitle":249,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":256,"briefSummary":258,"conditions":259,"keywords":263,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":52},"100616150","phase-1-a-study-testing-an-improved-dose-of-um171-to-help-make-cord-blood-transplants-more-effective-and-safe-100616150","NCT07301866","A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.","Single-site, Prospective, Open-label Phase I-II Study on Transplantation Using Cord Blood Treated With an Optimized Dose of UM171: Optimized ECT-001-CB.","ECT-001-CB-013","Inclusion Criteria:\n\n1. Subjects ≥ 18 and ≤ 67 years old,\n2. Patient with either i. High risk acute leukemia or myelodysplasia defined as expected 2 year OS or PFS \\\u003C 40% after a conventional allogeneic HSC transplant or ii. A hematologic malignancy requiring an allogeneic hematopoietic stem cell transplant and lack of a suitable HLA identical, haploidentical or 7\u002F8 HLA matched donor.\n3. Availability of an adequate CB for expansion:\n\n   i. ≥ 5\u002F8 HLA match when A, B, C and DRB1 are performed at the allele level.\n\n   ii. Minimal cell dose: TNC ≥ 1.5 x 107\u002Fkg, and CD34 ≥ 0.5 x 105\u002Fkg. iii. Needs to be erythrodepleted by bank prior to cryopreservation. iv. Must comply with local site regulations AND, come from a cord bank that is FACT, or AABB accredited, or FDA approved or eligible for NMDP IND (unless PI approves another bank).\n\n   v. To meet eligibility criteria, the patient's weight at time of cord selection will be used; however, if this weight has increased by more than 5% at time of admission to hospital and with the new weight the patient no longer meets eligibility criteria for cell dose, LI approval will be required to move forward with the selected cord. Every attempt will be made to always use the most recent weight in cord selection\n4. Patients with adequate physical function as measured by:\n\n   i. Karnofsky score ≥ 70% ii. Hematopoietic comorbidity index (HCT-CI): 0-3 for 2nd transplant and age 60-65 years, 0-5 if \\\u003C60 years old, and 0-2 if 66-67 years.\n\n   iii. Adequate cardiac function: Left ventricular ejection fraction ≥ 40% within 60 days prior to start of conditioning regimen iv. Adequate pulmonary function: Forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and diffusing capacity corrected for hemoglobin (DLCOc) ≥ 50% of predicted within 60 days prior to start of conditioning regimen.\n\n   v. Adequate hepatic function: Bilirubin \\\u003C 2 x ULN unless felt to be related to Gilbert's disease or hemolysis; AST and ALT ≤ 2.5 x ULN (the PI may approve up to 3 times ULN) ; alkaline phosphatase ≤ 5 x ULN.\n\n   vi. Adequate renal function: Estimated or measured creatinine clearance ≥ 60 ml\u002Fmin\u002F1.73m2.\n5. A back up graft must have been identified prior to initiation of conditioning regimen.\n6. Signed written informed consent.\n7. Female patients of childbearing potential must have a negative serum pregnancy test within 30 days of enrolment and within 30 days of starting of preparative regimen; patient must be willing to use an effective contraceptive method while enrolled in the study.\n\nExclusion Criteria:\n\n1. Allogeneic or autologous myeloablative transplant within last 6 months.\n2. Patients with inadequate physical function as measured by:\n\n   i. Active, uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of either progression of clinical symptoms or radiologic findings or lack of evidence of response to therapy).\n\n   ii. Presence of a malignancy other than the one for which the HSC transplant is being performed, with an expected survival estimated to be less than 75% at 5 years.\n\n   iii. Seropositivity for HIV. iv. Hepatitis B or C infection with measurable viral load. Patients with hepatitis B or C infection regardless of viral load require clear documentation of absence of cirrhosis by either fibroscan or biopsy.\n\n   v. Liver cirrhosis.\n3. Positive anti-donor HLA antibodies with MFI above 1500 against the selected CB (PI may approve an MFI up to 5000; if above 2500, desensitization is strongly recommended)\n4. Use of an investigational agent within 30 days (defined as a drug not approved by Health Canada or FDA regardless of indication) of start of chemotherapy unless documented approval obtained from Sponsor.\n5. Presence of ≥30% blasts in bone marrow or ≥ 0.5 x109\u002FL blasts in circulating blood\n6. Active central nervous system involvement or chloroma \\> 2 cm.","67 Years",{"count":255,"type":22},7,[257,61],"PHASE1","This clinical study is testing a new way to improve stem cell transplants for adults with high-risk blood cancers, such as leukemia or myelodysplasia, who do not have a suitable donor. The transplant uses stem cells from umbilical cord blood that have been expanded in the lab using a molecule called UM171. Previous studies showed that UM171 helps these cells grow and work better, leading to faster blood count recovery and fewer complications.\n\nIn this study, researchers are testing whether increasing the dose of UM171 during the lab expansion process can make the transplant less toxic. The hypothesis is that using a higher dose of UM171 to expand cord blood stem cells will help patients recover blood counts faster after transplant by improving the growth and function of the cells. This may lead to better immune recovery, fewer infections, shorter hospital stays, and improved overall outcomes.\n\nOnly seven patients will be enrolled, and they will be followed for one year after their transplant.",[260,261,262],"Acute Leukemia, High Risk","Myelodysplastic Syndromes, High Risk","Hematologic Malignancy Requiring an Allogeneic Hematopoietic Stem Cell Transplant Lacking a Donor",[264,265,266,267,268,269,270],"High risk hematologic malignancy","Cord blood transplant","UM171","ECT-001-CB","Lack of donor for stem cell transplant donor","Acute leukemia","Myelodysplastic syndrome","2025-12-22",{"date":273,"type":44},"2025-12-24",{"date":275,"type":44},"2025-10-06",{"date":277,"type":22},"2028-03",{"name":50,"class":51},{"id":280,"slug":281,"hasResults":12,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":287,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":52},"100480358","pib-for-post-operative-analgesia-after-laparotomy--determining-the-optimum-dose-100480358","NCT05534945","PIB for Post-operative Analgesia After Laparotomy : Determining the Optimum Dose","Programmed Intermittent Epidural Bolus for Postoperative Analgesia After Laparotomy: Determining the Optimum Dose Using a Biaised Coin Up-and-down Sequential Allocation Protocol","PIBDOSE","Inclusion Criteria:\n\n* 18-85 years old\n* ASA I to III\n\nExclusion Criteria:\n\n* Contraindication to TEA: Coagulopathy, sepsis or local infection at the epidural insertion site, patient refusal\n* Inability to site the epidural catheter\n* Inability to use PCEA\u002FCommunication barrier\n* Daily opioid use\n* Planned postoperative admission to the intensive care unit\n* Patient refusal\n* Predefined criteria for exclusion after inclusion: Failure to obtain a sensory block to ice in the Post Anesthesia Care Unit (PACU)(see Methods), Reoperation within 1 postoperative day","85 Years",{"count":93,"type":22},[25],"Pain control after surgery is a crucial component of postoperative recovery. Thus, in open abdominal surgery, the use of TEA (Thoracic epidural analgesia) has become a gold standard. However, analgesia may still remain a challenge, especially in patients with large incision abdominal incisions.\n\nTo address this problem, the use of the PIEB (Programmed intermittent epidural bolus) mode has been proposed, because it offers a better spread of the epidural medication.\n\nOnly a few studies have evaluated the superiority of this PIEB mode in open abdominal surgery, yielding conflicting results. However, PIEB showed to be at least as effective in controlling pain as CEI, and clinical experience shows that it can be a valuable tool, especially in patients with a large laparotomy incision.\n\nHowever, the optimal dosage of the PIEB mode has never been determined, Furthermore, it is known whether men and women have the same dosage needs to achieve adequate analgesia since most studies have failed to account for sex-based differences in postoperative analgesia.\n\nHence, the main objective of this study will be to determine the optimal volume dose of the PIEB delivered at a fixed interval of 60 min in patients undergoing surgery using a large midline laparotomy incision. The optimal dose for male and female patients will be determined separately by evaluating men and women in two independent groups. We hypothesize that the optimal dose of the PIEB that will provide effective analgesia in 90% of patients on the first postoperative day will range between 5 and 10 mL, for both groups.\n\nThe primary outcome in both groups is successful analgesia. It is defined as a requirement of 5 or less patient-controlled epidural boluses between 8 AM and 8 PM on the first postoperative day.\n\nSecondary outcomes will be the incidence of motor block and hypotension, comparison of the level of sensory block according to group, comparison of patient satisfaction according to group and comparison of Quality of Recovery-15 score at 48h post-op according to group.",[292,293,294],"Acute Post Operative Pain","Laparotomy","Epidural Analgesia","2025-11-13",{"date":297,"type":44},"2025-11-14",{"date":299,"type":44},"2022-12-01",{"date":301,"type":22},"2026-12",{"name":50,"class":51},{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":307,"acronym":4,"eligibilityCriteria":308,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":309,"enrollmentInfo":310,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":312,"conditions":313,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":4},"100593999","patient-positioning-and-its-influence-on-bis-nol-and-cerebral-oxygenation-in-anesthetized-patients-100593999","NCT07013734","Patient Positioning and Its Influence on BIS, NOL, and Cerebral Oxygenation in Anesthetized Patients","Inclusion Criteria:\n\n* Fully consented, adult patients above 18 years old;\n* Supine positioning during the surgery;\n* Surgery requiring patient positioning with Vacuform mats.\n\nExclusion Criteria:\n\n* Patient with Body Mass Index (BMI) ≥ 35;\n* Patients over 80 years old.","80 Years",{"count":311,"type":22},64,"The goal of this observational study is to find out how changes in body position during surgery might affect brain monitoring results in patients who are under general anesthesia.The main question it aims to answer is:\n\n\\- Does patient positioning have an impact on Bispectral Index (BIS) and Nociception Level (NOL) index monitoring (which are values of awareness in anesthesized patients).\n\nParticipants will undergo their surgery as planned, except for these extra features:\n\n* Extra monitors placed to check brain activity, pain response, and brain oxygen levels.\n* Before the surgery, while the patient is asleep, the patient's table will be moved into two different positions for 2 minutes each to see if the values on the monitor change.\n\nParticipants will then have to answer a short questionnaire after surgery about their memories before and after the anesthesia.",[314],"Monitoring of Depth of Anesthesia","2025-06-02",{"date":317,"type":44},"2025-06-10",{"date":319,"type":22},"2025-08",{"date":321,"type":22},"2026-04",{"name":50,"class":51},{"id":324,"slug":325,"hasResults":12,"nctId":326,"briefTitle":327,"officialTitle":328,"acronym":329,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":331,"enrollmentInfo":332,"targetDuration":4,"studyType":23,"phases":334,"briefSummary":335,"conditions":336,"keywords":345,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":357,"locationsCount":52},"100591559","importance-of-arterial-measurement-sites-ipams-on-intraoperative-hemodynamic-management-100591559","NCT06982001","ImPortance of Arterial Measurement Sites (IPAMS) on Intraoperative Hemodynamic Management","Importance of Arterial Measurement Sites on Intraoperative Hemodynamic Management of Major Abdominal Surgeries and Artificial Intelligence-based Prediction of Arterial Gradient Using Peripheral Radial Pressure Waveform Analysis","IPAMS","Inclusion Criteria:\n\n* Patients between 18 and 90 years of age;\n* Major abdominal surgery via laparoscopy or laparotomy under general anesthesia - with or without concomitant use of regional or neuraxial anesthesia;\n* Expected anesthesia time of more than 120 minutes.\n\nExclusion Criteria:\n\n* Known peripheral severe vascular disease with subclavian artery stenosis,\n* Significant arterial gradient between arms with preoperative non-invasive bloop pressure measurements (\\>25 mm Hg of systolic blood pressure or 10 mm Hg of mean arterial pressure);\n* Inability or contraindications to insert arterial line on either arm (arteriovenous fistula, surgical sterility);\n* Known allergies, intolerance, other medical conditions that precludes the use of prescribed general anesthesia protocol for this trial;\n* Inability to communicate in French or English.","90 Years",{"count":333,"type":22},204,[25],"The goal of this clinical trial is to demonstrate the importance of arterial pressure measurement sites during major abdominal surgeries. This randomized controlled trial will compare arterial pressure measurements obtained from radial artery catheterization (the current standard method of monitoring) with those obtained from brachial artery catheterization (a more accurate reflection of central arterial pressure). At the end of the study, we are looking to answer the following questions:\n\n1. Does arterial pressure measurement sites influence the amount of vasopressors that is administered during major abdominal surgeries?\n2. What are the instances where there is a difference between peripheral (radial catheter) and central (brachial catheter) monitoring and what are the risk factors leading to the appearance of this radial-brachial pressure gradient?\n3. With the data collected, can artificial intelligence based analysis help predict the reliability of a radial monitoring and help guide clinicians on choosing a peripheral versus central arterial pressure monitoring site? All adult participants who are scheduled for elective major abdominal surgeries and meeting our inclusion criteria will be approached and included if they consent. Participants will be randomized 1:1 in the intervention group and the standard of care group. In the intervention group, the brachial arterial line will be used intraoperatively to guide vasopressor and fluid administration. A radial line will also be installed to measure the radial arterial pressure simultaneously, but will not be used to guide hemodynamic management. In the standard of care group, both lines will be installed just like in the intervention group, however, it is the radial arterial line that will guide fluid and vasopressor administration. In both groups, the anesthesia protocol will be standardized and the anesthesiologist will be blinded to the arterial pressure measurement site.",[337,338,339,340,230,341,342,343,344],"Perioperative Care","Hemodynamics","Monitoring Blood Pressure","Arterial Lines","Vasopressor","Fluid Management","Artificial Intelligence in Operating Room","Artificial Intelligence (AI)",[346,347,348,349,350],"Comparison of arterial catheterization sites on hemodynamic monitoring","Incidence of radial-brachial pressure gradient","Risk factors of radial-brachial pressure gradient","Effect of arterial catheterization sites on hemodynamic management","Effect of peripheral vs central arterial pressure measurements in intraoperative hemodynamic management","2025-05-13",{"date":353,"type":44},"2025-05-21",{"date":355,"type":22},"2025-09",{"date":162,"type":22},{"name":50,"class":51},{"id":359,"slug":360,"hasResults":12,"nctId":361,"briefTitle":362,"officialTitle":363,"acronym":364,"eligibilityCriteria":365,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":366,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":376,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":383,"lastUpdatePostDateStruct":384,"startDateStruct":386,"completionDateStruct":388,"leadSponsor":389,"locationsCount":4},"100580177","combining-virtual-reality-and-hypnosis-to-alleviate-chronic-pain-in-elderly-patients-with-hand-arthritis-100580177","NCT06833905","Combining Virtual Reality and Hypnosis to Alleviate Chronic Pain in Elderly Patients with Hand Arthritis","Combining Virtual Reality and Hypnosis to Alleviate Chronic Pain in Elderly Patients with Hand Arthritis: a Pilot Randomized Clinical Trial","VRHArthrisis","Inclusion Criteria:\n\n* Fluent in French\n* Being diagnosed with hand arthrisis\n* Reporting an invalidating chronic pain in hand related to the condition\n\nExclusion Criteria:\n\n* Experiencing a medical condition altering the ability to consent or participate in the study\n* Experiencing cognitive disorders; Experiencing sensory disorders (deafness, blindness)","100 Years",{"count":368,"type":22},80,[25],"The goal of this pilot randomized clinical trial is to test the efficacy of an intervention combining virtual reality and hypnosis on decreasing pain and improving quality of life in elderly patients with hand arthritis. The main questions it aims to answer are:\n\n* Does the intervention allow for an improvement of patient reported outcomes related to pain and quality of life?\n* Does the intervention allow for an improvement of physiological variables related to pain? Researchers will compare intervention group to a passive control group (i.e., waiting list with treatment as usual).\n\nParticipants in the intervention group will be provided a virtual reality headset allowing them to beneficiate from the virtual reality and hypnosis modules.",[372,373,374,375],"Arthritis","Arthritis\u002FArthrosis","Arthritis, Rheumatoid","Elderly",[377,378,379,380,381,382],"virtual reality","hypnosis","arthritis","pain","quality of life","elderly","2025-03-17",{"date":385,"type":44},"2025-03-19",{"date":387,"type":22},"2025-04",{"date":355,"type":22},{"name":50,"class":51},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":396,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":398,"targetDuration":4,"studyType":152,"phases":4,"briefSummary":400,"conditions":401,"keywords":402,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":52},"100515296","transitioning-to-home-or-in-center-dialysis-100515296","NCT05989659","Transitioning to Home or In-center Dialysis","Transitioning Patients with Advanced Chronic Kidney Disease to Home or In-center Dialysis: Understanding the Experience and Quality of Life for Patients and Their Caregivers","TRANSIT-CARE","Inclusion Criteria:\n\n1. Adults followed in advanced CKD clinic,\n2. estimated glomerular filtration rate (eGFR) \\\u003C12 mL\u002Fmin\u002F1.73m2 103,\n3. Have chosen their dialysis modality,\n4. Understand English or French.\n\nExclusion Criteria:\n\n1. Orientation toward conservative treatment,\n2. Planned kidney transplantation \\\u003C 6 months,\n3. Unable to provide consent due to severe cognitive or psychiatric disease,\n4. Previous treatment with dialysis \\> 3 months,\n5. Life expectancy \\\u003C 6 months",{"count":399,"type":22},420,"For people with advanced kidney disease, deciding which type of dialysis is best can be challenging. Studies have shown that quality of life is very important to patients. It is thought that the quality of life of people receiving their dialysis at home may be better than the one of people receiving dialysis in a hospital. However, how the start of dialysis changes the quality of life of people who choose home dialysis in comparison to people choosing dialysis in a hospital is still unknown.\n\nTRANSIT-CARE is a prospective mixed methods study following adult with advanced kidney disease who progress to dialysis and receive home or hospital-based dialysis. This study aims to examine the trajectory and change in patients' quality of life and their frailty status (health, mobility and function) before start of dialysis and up to 12-month after start. Differences between people doing home dialysis and hospital-based dialysis will be assesses taking into account people's characteristics including their gender and socio-demographics characteristics. The study will include questionnaires to measure quality of life and tools to evaluate frailty. Additionally, semi-structured interviews will be done with a diverse group of patients and caregivers before and after the initiation of dialysis to better understand their experience of transitioning to dialysis.",[201],[403,203,204,404,405,406,178,407],"Chronic Kidney Disease","Home Dialysis","Peritoneal Dialysis","Home Hemodialysis","Mixed Methods","2025-02-12",{"date":410,"type":44},"2025-02-14",{"date":412,"type":44},"2023-01-01",{"date":414,"type":22},"2027-12-30",{"name":50,"class":51},{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":23,"phases":424,"briefSummary":425,"conditions":426,"keywords":430,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":52},"100578935","development-of-an-intervention-integrating-procedures-combining-hypnosis-and-virtual-reality-in-the-support-of-patients-with-hematological-cancer-100578935","NCT06817759","Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological Cancer","Study Protocol for the Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Myeloma and Lymphoma During Stem Cell Transplant: a Pilot Randomized Clinical Trial","Inclusion Criteria:\n\n* Being 18 years of age or older\n* Suffering from multiple myeloma or lymphoma eligible for transplant\n* Understanding French\n\nExclusion Criteria:\n\n* Deafness\n* Blindness\n* Confusion or psychopathological disorders (for example, schizophrenia) that may impair communication",{"count":93,"type":22},[25],"Research into cancer patients has shown that quality of life is significantly altered by the disease and its associated treatments and is also reported to be a predictor of significant emotional distress. Blood cancer patients are among those most affected in terms of quality of life, facing stem cell transplantation after high-dose chemotherapy, a treatment that is recognized as one of the most stressful of cancer therapy, due to the many adverse effects, including pain, and the uncertainty linked to the fear of graft failure. Hypnosis interventions are proving effective in treating common side effects: nausea, pain, fatigue, anxiety, depressive symptoms and improving overall quality of life, and other interventions, based on virtual reality, have shown promising effects on patients' distress and acute pain. The aim of this study is to evaluate the effects of an intervention program combining hypnosis and virtual reality in assisting myeloma and lymphoma patients during stem cell transplantation, with a view to improving their quality of life during this period. The project aims to assess the validity of the intervention, and to evaluate the effects of the intervention on patients' anxiety, pain and fatigue during transplantation. The validity of the intervention will be measured by a questionnaire assessing the relevance and acceptability of the intervention, expected effects, and practical implementation. Socio-demographic and clinical data will be collected from patients, including axiety, pain, fatigue and quality of life, studied at pre (one week after transplantation) and post (one month after transplantation) intervnention, and at follow-up (three month after transplantation).",[427,428,429],"Blood Cancer","Multiple Myeloma (MM)","Lymphoma",[431,432,433,434,435,436,378,377,437,438,380,439],"Virtual reality hypnosis","Quality of life","Blood cancer","Oncology","multiple myeloma","lymphoma","hematology","anxiety","stem cells transplantation","2025-02-04",{"date":442,"type":44},"2025-02-10",{"date":444,"type":22},"2025-02",{"date":446,"type":22},"2025-12",{"name":50,"class":51},{"id":449,"slug":450,"hasResults":12,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":23,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":466,"locationsCount":52},"100537578","self-hypnosis-training-for-chronic-pain-management-100537578","NCT06279650","Self-hypnosis Training for Chronic Pain Management","Self-hypnosis Training in Chronic Pain Management: A Qualitative Exploratory Study of Patients Practicing Self-hypnosis","Inclusion Criteria:\n\n* Inclusion criteria were to have participated in the past year in the self-hypnosis training program and to agree to take part in these research interviews.\n* be 18 years of age or older;\n* have received one of the above diagnoses, confirmed by medical record review or physician confirmation;\n* report pain that has been present for at least 3 months;\n* have a pain intensity over the last 24 hours (24h pain) of at least 4 on a Numerical Rating Scale (NRS) from 0 to 10 at baseline;\n* be able to read, speak and understand French;\n* have Internet access and be able to participate in a telepractice intervention group and complete online questionnaires.\n\nExclusion Criteria:\n\n* have deafness and\u002For severe cognitive impairment that may impair communication;\n* have current or recent psychiatric instability (e.g., active suicidal ideation, active delusional or psychotic thoughts) that could interfere with participation, as assessed by a clinical psychologist.",{"count":93,"type":22},[25],"Title: Self-hypnosis training in chronic pain management: A pilot study Our primary objective concerns the effect of hypnosis intervention on change in 24h pain between T0 (pre-intervention) and T4 (3-month follow-up). The secondary objectives concern the effects of the intervention on (i) change in 24h pain between T0 and T5 (6-month follow-up), (ii) changes from T0 in measures of the functional impact of pain, (iii) changes from T0 in anxiety-depression scores and (iv) changes from T0 in quality of life.\n\nThe study design is a Randomized efficacy pilot study. The study focuses on patients practicing self-hypnosis within HMR groups. The study population is pain clinic patients. The sample size is 60 pain clinic patients. Study duration: February 2024 - December 2024. Center responsible for the study: Centre de Recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR) - CEMTL, Montreal, Quebec, Canada.\n\nAdverse events: none expected.",[459],"Hypnosis, Chronic Pain Management","2025-01-25",{"date":462,"type":44},"2025-01-28",{"date":464,"type":44},"2024-02-01",{"date":446,"type":22},{"name":50,"class":51},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":309,"enrollmentInfo":474,"targetDuration":4,"studyType":23,"phases":476,"briefSummary":477,"conditions":478,"keywords":4,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":52},"100331527","dexmedetomidine-and-ketamine-in-vats-surgery-100331527","NCT03596424","Dexmedetomidine and Ketamine in VATS Surgery","Impact of Dexmedetomidine and Ketamine and Their Combination for the Reduction of Postoperative Morphine Requirements After VATS Surgery","Inclusion Criteria:\n\n* Patients aged 18-80 years old\n* American Society of Anesthesiology physical status I-III\n* Elective Video-Assisted Thoracic Surgery for pulmonary resection\n\nExclusion Criteria:\n\n* Patients for which a regional anesthesia technique is planned for postoperative analgesia.\n* Patients taking beta-blockers preoperatively.\n* Patients with chronic pain taking \\>60 mg morphine PO daily (or its equivalent).\n* Patients taking pregabalin, gabapentin, amitryptillin, nortryptillin and\u002For duloxetin.\n* Documented allergy to ketamine and\u002For dexmedetomidine.\n* Pregnancy\n* Inability to give informed consent\n* Linguistic barrier.\n* Patient refusal",{"count":475,"type":22},120,[25],"Postoperative pain after VATS surgery is significant and associated with moderate to high post operative morphine requirements, which can cause opioid related side effects and delay postoperative recovery. To reduce this requirement, multimodal analgesia with non opioid medication such as dexmedetomidine and ketamine can be used. These drugs have demonstrated significant opioid-sparing properties after various types of surgeries. However, very little is known about their ability to do so in VATS surgery. Also, their relative opioid-sparing properties have not been compared, and it is not known whether their combined use can lead to an additional opioid-sparing effect. The primary goal of this study will be to determine the impact of a combined intra operative infusion of ketamine and dexmedetomidine on postoperative morphine requirements in patients undergoing elective VATS, compared to both these drugs infused separately.\n\nThe hypothesis is that this combined infusion will lead to a 30% further reduction in morphine requirements, 24h after surgery, compared to both these drugs infused separately.",[479,480],"Postoperative Pain","Opioid Use","2024-11-27",{"date":483,"type":44},"2024-12-02",{"date":485,"type":44},"2018-02-01",{"date":487,"type":22},"2026-07-01",{"name":50,"class":51},{"id":490,"slug":491,"hasResults":12,"nctId":492,"briefTitle":493,"officialTitle":494,"acronym":495,"eligibilityCriteria":496,"healthyVolunteers":172,"sex":18,"minAge":19,"maxAge":309,"enrollmentInfo":497,"targetDuration":4,"studyType":23,"phases":499,"briefSummary":500,"conditions":501,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":52},"100568666","the-impact-of-a-dexmedetomidine-perfusion-on-intraoperative-remifentanil-consumption-100568666","NCT06684197","The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption","The Impact of a Dexmedetomidine Perfusion on Intraoperative Remifentanil Consumption: a Randomized Controlled Trial","DEXREM","Inclusion Criteria:\n\n* ASA 1-3\n* Laparascopic surgery (including general surgery, gynecology, urology) a small abdominal incision (less than 5 cm) will be tolerated.\n\nExclusion Criteria:\n\n* Patient refusal\n* Chronic use of opioids\n* Allergy to medication used in the trial\n* Pregnant or breastfeeding women\n* Contraindications to dexmedetomidine (Bradycardia, arrythmia or pace- maker, severe ventricular dysfunction)",{"count":498,"type":22},72,[25],"Opioids analgesic are the gold standard for intraoperative pain management. Their short- and long-term adverse effect motivate anesthesiologists to explore opioid sparing strategies. Dexmedetomidine is a highly selective α2 adrenergic receptor agonist that could help minimize opioid consumption both intraoperative and postoperative due to its sedative, analgesic and sympatholytic properties. This new randomized controlled trial (RCT) will answer the question whether an intraoperative dexmedetomidine infusion compared to placebo has a clinically significant impact on intraoperative remifentanil consumption during a laparoscopic abdominal elective surgery.",[502,503,504,505,506],"Dexmedetomidine","Total Intravenous Anesthesia","Remifentanil Consumption","Remifentanil","Laparoscopic Abdominal Surgery","2024-11-08",{"date":509,"type":44},"2024-11-12",{"date":511,"type":22},"2024-11",{"date":513,"type":22},"2025-11",{"name":50,"class":51},{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":521,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":148,"minAge":19,"maxAge":4,"enrollmentInfo":523,"targetDuration":4,"studyType":23,"phases":524,"briefSummary":525,"conditions":526,"keywords":529,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":536,"startDateStruct":538,"completionDateStruct":540,"leadSponsor":542,"locationsCount":52},"100556254","virtual-reality-for-anxiolysis-and-pharmacological-sparing-100556254","NCT06522711","Virtual Reality for Anxiolysis and Pharmacological Sparing","Virtual Reality as a Strategy for Intra-operatory Anxiolysis and Pharmacological Sparing in Patients Undergoing Breast Surgeries : the V-RAPS Randomized Controlled Trial","V-RAPS","Inclusion Criteria:\n\n* Fully consented female patients above the age of 18 years;\n* Undergoing elective, awake, breast surgery performed under paravertebral block.\n\nExclusion Criteria:\n\n* Hearing or visual impairment;\n* History of epilepsy, seizure or severe dizziness;\n* Severe mental impairment;\n* Recent eye or facial surgery or wounds;\n* Inability to use the VR hand controller.",{"count":150,"type":22},[25],"The goal of this clinical trial is to learn if virtual reality can reduce propofol requirements in adult, female patients undergoing elective breast surgery under regional anesthesia. The main question it aims to answer is:\n\nCan virtual reality immersion reduce intra-operative propofol requirements in adult female patients undergoing elective breast surgery under regional anesthesia?\n\nResearchers will compare time and weight-adjusted average propofol requirements in both the intervention group and the control group to see if there is a reduction in sedative usage in the group using the virtual reality device.\n\nParticipants will be randomly assigned to either a virtual reality (intervention) group or a control group.\n\n* The patients in the virtual reality group will have a virtual reality headset on during the surgery with a preselected scenario of their choice.\n* Both groups will have access to patient-controlled sedation under the supervision of an anesthesiologist and will be permitted to self-administer propofol boluses as needed.",[527,528],"Virtual Reality","Propofol",[530,531,532,533,528,534],"Virtual reality","Anxiety","Patient-controlled sedation","Pain","Breast surgery","2024-07-25",{"date":537,"type":44},"2024-07-26",{"date":539,"type":22},"2024-09-01",{"date":541,"type":22},"2026-09-01",{"name":50,"class":51},{"id":544,"slug":545,"hasResults":12,"nctId":546,"briefTitle":547,"officialTitle":548,"acronym":549,"eligibilityCriteria":550,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":23,"phases":553,"briefSummary":554,"conditions":555,"keywords":557,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":535,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":566,"leadSponsor":568,"locationsCount":52},"100556253","optimizing-research-data-acquisition-with-smart-pill-bottles-100556253","NCT06522698","Optimizing Research Data Acquisition With Smart Pill Bottles","Optimizing Research Data Acquisition With Smart Pill Bottles: A Feasibility and Implementation Study","SPB","Inclusion Criteria:\n\n* All consenting adult patients (age \\>17 years) undergoing major abdominal surgery via laparotomy (any open surgery involving the abdominal compartment or its wall, excluding appendectomies, inguinal hernia repairs, abdominal wall hernia repairs, and incisional hernia repairs)\n\nExclusion Criteria:\n\n* Patients enrolled in the historical cohort (POCAS study)\n* Patients currently participating in another study\n* Patients planned to undergo additional surgery within 90 days after the surgery\n* Patients who do not understand French or English.\n* Patients planned to be redirected to a secondary care or rehabilitation establishment following discharge\n* Patients with diagnosed cognitive impairment",{"count":552,"type":22},155,[25],"The goal of this clinical trial is to learn if smart pill bottles can be used as a tool to optimize data collection in clinical trials by increasing the quality of data collected and limiting the associated cost. The main questions it aims to answer are:\n\nIs the use of smart pill bottles a feasible method of data collection in clinical trials in terms of patient adherence.\n\nIs the data collected by the smart pill bottles of higher quality than that collected through human resources? What is the impact of the use of smart pill bottles on the costs involved in clinical trials ?\n\nResearchers will collect data on postoperative opioid medication consumption with the smart pill bottle and assess the adherence of patients to the device along with the quality of data collected and the costs involved in the process.\n\nParticipants will:\n\nUse the smart pill bottle to consume opioid medication following surgery for 3 months At the end of the 3 month period, the group will have filled out surveys detailing their opioid consumption, surgical pain and other relevant information.",[556,480],"Post Operative Pain",[558,559,560,561,562,563],"Major abdominal surgery","Connected Technology","Chronic Pain","Postoperative pain","Opioid consumption","Smart Pill Bottles",{"date":537,"type":44},{"date":539,"type":22},{"date":567,"type":22},"2025-07-01",{"name":50,"class":51},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":577,"targetDuration":578,"studyType":152,"phases":4,"briefSummary":579,"conditions":580,"keywords":582,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":52},"100555968","prospective-validation-of-intraoperative-blood-pressure-monitors-100555968","NCT06518980","Prospective Validation of Intraoperative Blood Pressure Monitors","Prospective Validation of Intraoperative Blood Pressure Monitors: the Influence of Site and Execution Strategy. The PROMISES Trial","PROMISES","Inclusion Criteria:\n\n* Fully consented, adult patients above 18 years old;\n* Undergoing surgery of duration time expected at least 60 minutes using general anesthesia;\n* Supine positioning during the surgery;\n* Surgery requiring an arterial line;\n* Both arms available for instrumentation during the surgery.\n\nExclusion Criteria:\n\n* Atrial fibrillation, multifocal atrial tachycardia, or any other irregular hear rythm;\n* Gradient of mean arterial pressure between the two arms greater than 5 mm Hg, as measured during the recruitment process.",{"count":93,"type":22},"1 Day","This observational study aims to identify the incidence and importance of discrepancies between measurements of intraoperative invasive and noninvasive blood pressure monitoring in patients undergoing non-cardiac surgeries under general anesthesia . The main questions it aims to answer are :\n\n* The importance of the differences, in mmHg, between the non-invasive and invasive blood pressure measurements (NIBP-IBP) on systolic, diastolic and mean arterial pressure.\n* Identify the predictive factors associated with these differences.",[230,581],"Blood Pressure",[583,584,585,586],"anesthesia","blood pressure","noninvasive blood pressure","invasive blood pressure","2024-07-19",{"date":535,"type":44},{"date":590,"type":22},"2024-07",{"date":592,"type":22},"2025-10",{"name":50,"class":51},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":18,"minAge":91,"maxAge":4,"enrollmentInfo":602,"targetDuration":4,"studyType":23,"phases":604,"briefSummary":605,"conditions":606,"keywords":608,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":615,"leadSponsor":617,"locationsCount":52},"100555729","seniors-intraoperative-management-under-locoregional-anesthesia-integrating-virtual-reality-100555729","NCT06515873","Seniors' Intraoperative Management Under Locoregional Anesthesia Integrating Virtual Reality","Evaluating the Acceptability of Virtual Reality Headsets During Surgery Under Spinal Anesthesia in Elderly Patients. Seniors' Intraoperative Management Under Locoregional Anesthesia Integrating Virtual Reality (SILVR)","SILVR","Inclusion Criteria:\n\n* Fully consented patients over 65 years old\n* Undergoing elective surgery that requires spinal anesthesia.\n\nExclusion Criteria:\n\n* Hearing or visual impairment\n* History of epilepsy, seizure, or severe dizziness\n* Severe mental impairment\n* Recent eye or facial surgery or wounds\n* Inability to use their hands",{"count":603,"type":22},55,[25],"This study aims to evaluate the acceptability of intraoperative virtual reality in elderly patients under spinal anesthesia.",[527,607],"Spinal Anesthesia",[609,610],"Elderly patient","Acceptability","2024-07-17",{"date":613,"type":44},"2024-07-23",{"date":590,"type":22},{"date":616,"type":22},"2025-03",{"name":50,"class":51},{"id":619,"slug":620,"hasResults":12,"nctId":621,"briefTitle":622,"officialTitle":623,"acronym":624,"eligibilityCriteria":625,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":91,"enrollmentInfo":626,"targetDuration":4,"studyType":23,"phases":627,"briefSummary":629,"conditions":630,"keywords":633,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":640,"completionDateStruct":642,"leadSponsor":644,"locationsCount":52},"100538478","phase-4-impact-of-administration-of-esmolol-on-nociception-level-guided-control-of-nociception-100538478","NCT06291363","Impact of Administration of Esmolol on Nociception Level-guided Control of Nociception.","Impact of Continuous Intraoperative Administration of Esmolol on Nociception Level-guided Control of Nociception. The EsmoNOL Randomized Controlled Trial","ESMONOL","Inclusion Criteria:\n\n* Fully consented, American Society of Anesthesiologists Classification Score 1-3 patients from 18yo to 65yo\n* Undergoing laparoscopic surgery associated with sub umbilical mini-laparotomy. Eligible surgeries will be hysterectomy (excluding vaginal approach) and left hemicolectomy, of duration time expected under 180 minutes, under general anesthesia\n* No allergy to one of the medications used in this study\n\nExclusion Criteria:\n\nContraindication to the use of the study drug (esmolol) is an exclusion criterion :\n\n* Hypotension\n* Sinus bradycardia\n* Sick sinus syndrome\n* Second and third degree A-V block\n* Pulmonary hypertension\n* Right ventricular failure secondary to pulmonary hypertension\n* Decompensated heart failure\n* Cardiogenic shock\n* Nontreated pheochromocytoma\n* Known hypersensitivity to esmolol or any of the inactive ingredients of the product\n* Allergy to esmolol or other beta blockers (cross-sensitivity is possible)\n* Renal dysfunction\n* Airway disease such as asthma or chronic obstructive pulmonary disease\n* Thyrotoxicosis\n* Myasthenia gravis\n* Raynaud's disease or peripheral circulatory disorder\n\nOther situations leading to exclusion :\n\n* Severe mental impairment\n* Chronic use of opioids, β-adrenergic receptors antagonists\n* High risk of conversion to laparotomy according to the surgical team (\\>25%)\n\nPatients will automatically be excluded after recruitment if they withdraw their consent, or if laparoscopy is converted to laparotomy.",{"count":311,"type":22},[628],"PHASE4","This study aims to evaluate esmolol's perfusion impact during induction and maintenance of general anesthesia, using Nociception-Level-guided control of nociception, in adult patients undergoing laparoscopic and lower abdominal surgery, on intraoperative remifentanil consumption and postoperative pain in the Post-Anesthesia Care Unit.",[631,230,632],"Opioid Use, Unspecified","Nociceptive Pain",[634,635,636,232],"opioid sparing anesthesia","beta blockers","nociception monitoring","2024-07-15",{"date":639,"type":44},"2024-07-16",{"date":641,"type":44},"2024-04-16",{"date":643,"type":22},"2025-03-04",{"name":50,"class":51},{"id":646,"slug":647,"hasResults":12,"nctId":648,"briefTitle":649,"officialTitle":650,"acronym":651,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":18,"minAge":653,"maxAge":4,"enrollmentInfo":654,"targetDuration":4,"studyType":23,"phases":656,"briefSummary":657,"conditions":658,"keywords":660,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":666,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":670,"locationsCount":52},"100425889","neurocognitive-disorders-after-major-surgery-in-elderly-100425889","NCT04825847","Neurocognitive Disorders After Major Surgery in Elderly","Effect of Electroencephalography-guided Anesthesia on Neurocognitive Disorders in Elderly Patients Undergoing Major Non-cardiac Surgery: a Randomized Clinical Trial","POEGEA","Inclusion Criteria:\n\n* Patients 70 years of age or older,\n* Major gynecologic, abdominal, urologic, thoracic or orthopedic surgery via laparoscopy or laparotomy under general anesthesia - with or without concomitant use of regional or neuraxial anesthesia -,\n* Expected anesthesia time of more than 60 minutes,\n* Seen for assessment by internal medicine and\u002For anesthesiology at the preoperative clinic (CIEPC)\n\nExclusion Criteria:\n\n* Known diagnosis of dementia or other neurological, psychiatric, developmental or medical condition that resulted in documented severe cognitive impairment,\n* Emergency surgery,\n* Significant auditory or visual impairment that precludes participation in cognitive testing,\n* Known allergy or intolerance or other medical condition that precludes the use of prescribed general anesthesia protocol for this study,\n* Inability to communicate in French or English.","70 Years",{"count":655,"type":22},314,[25],"The objective of the study is to investigate, in patients aged 70 years and over undergoing major non-cardiac surgery, the effect of electroencephalic (EEG)-guided anesthesia on postoperative neurocognitive disorders when controlling for intraoperative nociception, personalized blood pressure targets and using full information provided by the processed EEG monitor (including burst suppression ratio, density spectral array and raw EEG waveform).\n\nThis prospective, randomized, controlled trial will be conducted in a single Canadian university hospital. Patients aged 70 years and over, undergoing elective major non-cardiac surgery will be included. The administration of sevoflurane will be adjusted to maintain a BIS value between 40 and 60, a suppression Ratio at 0%, a direct EEG display without any suppression time and a spectrogram with most of the EEG wave frequency within the alpha, theta and delta frequencies in the EEG-guided group. In the control group sevoflurane will be administered to achieve an age-adjusted minimum alveolar concentration of \\[0.8-1.2\\]. A nociception monitor will guide intraoperative opioids' infusion and individual blood pressure targets will be personalized in both groups. The primary endpoint is the incidence of neurocognitive disorder (NCD) at postoperative day 1 evaluated by the Montréal Cognitive Assessment. Secondary endpoints include the incidence of postoperative neurocognitive disorder at different timepoints and the evaluation of cognitive trajectories among EEG-guided and control groups.",[230,659],"Neurocognitive Disorders",[230,661,662,663,664,665],"Processed EEG Monitor","Neurocognitive disorders","Major surgery","Burst Suppression","MoCA",{"date":611,"type":44},{"date":668,"type":44},"2021-11-24",{"date":319,"type":22},{"name":50,"class":51},{"id":672,"slug":673,"hasResults":12,"nctId":674,"briefTitle":675,"officialTitle":676,"acronym":677,"eligibilityCriteria":678,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":679,"targetDuration":4,"studyType":23,"phases":681,"briefSummary":682,"conditions":683,"keywords":685,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":691,"lastUpdatePostDateStruct":692,"startDateStruct":694,"completionDateStruct":696,"leadSponsor":698,"locationsCount":52},"100540589","towards-remission-and-full-recovery-from-obsessive-compulsive-disorder-100540589","NCT06318806","Towards Remission and Full Recovery From Obsessive-compulsive Disorder","Towards Remission and Full Recovery From Obsessive-compulsive Disorder: Investigating the Efficacy of Inference-Based Cognitive-Behavioral Therapy When Standard Treatment Has Failed","RCT2023","Inclusion criteria:\n\n1. a primary diagnosis of OCD according to DSM-5 criteria.\n2. a score ≥ 18 on the Y-BOCS\n3. age ≥ 18.\n4. no change in medication during the 8 weeks before treatment for antidepressants (4 weeks for anxiolytics).\n5. willingness to keep medication stable while participating in the study.\n6. not undergoing a concurrent psychological treatment.\n7. access to a computer or phone with internet access.\n\n   Exclusion criteria:\n8. evidence of a high level of suicidal ideation, suicidal intent or previous suicide attempts.\n9. past or present psychotic or bipolar disorder.\n10. neurocognitive disorder, pervasive developmental disorder or intellectual disability of a severity judged to significantly interfere with treatment and\u002For requiring treatment first.\n11. substance abuse disorder of a severity judged to significantly interfere with treatment and\u002For requiring treatment first.",{"count":680,"type":22},160,[25],"Obsessive-compulsive disorder (OCD) is a disabling psychiatric illness that is characterized by distressing obsessional thoughts and time-consuming compulsive rituals. Exposure and Response Prevention (ERP) is a first-line psychological treatment of choice that requires patients to face their fears by being exposed to feared stimuli. This treatment has been shown to reduce symptoms in a significant proportion of patients. However, it is considered a difficult treatment and only a minority reach remission. Residual symptoms typically remain, or reappear after treatment, which is a risk for relapse. Inference-based Cognitive Behavioral Therapy (I-CBT) is a promising evidence-based treatment developed to overcome these limitations. I-CBT has already been found to be as effective as ERP and significantly more acceptable and easier to adhere to. There is also evidence that I-CBT is more effective for subgroups of patients. Consequently, the current research project is focused on improving treatments outcomes for those provide those who have previously unable to reach remission of their symptoms with ERP. Following an initial treatment with ERP, those that have been unable to reach remission, will be randomized to either I-CBT or more ERP. It is expected that I-CBT will be significantly more effective than providing patients with more of the same. In addition, the study aims to predict treatment outcome in order to be able to tell in advance which patients do not respond to ERP. The project is designed to maximize beneficial health outcomes with a stepped-care approach to treatment, but also to work towards a more personalized choice by being able to match patients in advance with the treatment that works best for them",[684],"Obsessive-Compulsive Disorder",[686,687,688,689,690],"Obsessive-Compulsive Disorder,","Treatment outcome","Predictors of Outcome","Exposure and Response Prevention","Inference-based Cognitive Behavioral Therapy","2024-07-04",{"date":693,"type":44},"2024-07-08",{"date":695,"type":44},"2024-07-01",{"date":697,"type":22},"2029-09-30",{"name":50,"class":51},""]